Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® implant technology will be presented at the 11th Symposium Sport Medizin und Mee(h)r, on February 7 – 9 in Kiel, Germany. Dr. med. A. Losch from MedBaltic, Kiel, will hold the presentation with the title “Patient-specific partial joint replacement and sports ability”.

“We are excited over the fact that the European Episealer® users are continuing to present and discuss their experiences from using the Episealer® knee implant” says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

CisionBlockPro\Cision\FeedItem Object
(
    [HtmlCompanyInformation:protected] => 
    [HtmlContact:protected] => 
    [HtmlTitle:protected] => <h1><strong><span style="font-family:arial,helvetica,sans-serif">Episealer® to be presented at sports medicine meeting in Germany</span></strong></h1>
    [HtmlHeader:protected] => 
    [HtmlIntro:protected] => 
    [Body:protected] => Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® implant technology will be presented at the 11[th] Symposium Sport Medizin und Mee(h)r, on February 7 – 9 in Kiel, Germany. Dr. med. A. Losch from MedBaltic, Kiel, will hold the presentation with the title “Patient-specific partial joint replacement and sports ability”.
“We are excited over the fact that the European Episealer® users are continuing to present and discuss their experiences from using the Episealer® knee implant” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
 
    [HtmlBody:protected] => <p style="margin-bottom:10px"><span style="font-size:10pt"><span style="line-height:107%"><span style="font-family:arial,helvetica,sans-serif">Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® implant technology will be presented at the 11<sup>th</sup> <em>Symposium Sport Medizin und Mee(h)r</em>, on February 7 – 9 in Kiel, Germany. Dr. med. A. Losch from MedBaltic, Kiel, will hold the presentation with the title <em>“Patient-specific partial joint replacement and sports ability”</em>. </span></span></span></p>
<p style="margin-bottom:10px"><span style="font-size:10pt"><span style="line-height:107%"><span style="font-family:arial,helvetica,sans-serif"><em><span style="font-family:arial,helvetica,sans-serif">“We are excited over the fact that the European Episealer® users are continuing to present and discuss their experiences from using the Episealer® knee implant”</span></em> says Pål Ryfors, CEO Episurf Medical.</span></span></span></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-size:10pt"><strong><span style="font-family:arial,helvetica,sans-serif">For more information, please contact:</span></strong></span></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">Pål Ryfors, CEO, Episurf Medical</span><br>
<span style="font-family:arial,helvetica,sans-serif">Tel:</span><span style="font-family:arial,helvetica,sans-serif">+46 (0) 709 62 36 69</span><br>
<span style="font-family:arial,helvetica,sans-serif">Email:&nbsp;</span><a href="mailto:pal.ryfors@episurf.com"><span style="font-family:arial,helvetica,sans-serif">pal.ryfors@episurf.com</span></a></span></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-size:10pt"><strong><span style="font-family:arial,helvetica,sans-serif">About Episurf Medical</span></strong></span></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-size:10pt"><em><span style="font-family:arial,helvetica,sans-serif">Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</span></em></span></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt">&nbsp;</p>
    [ServiceCategories:protected] => Array
        (
            [0] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => Twitter
                    [Name:protected] => Twitter
                    [Value:protected] => 9341
                )
            [1] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => LinkedIn
                    [Name:protected] => LinkedIn
                    [Value:protected] => 12134
                )
            [2] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => Facebook
                    [Name:protected] => Facebook
                    [Value:protected] => 9307
                )
        )
    [LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
    [CompanyInformation:protected] => 
    [Contact:protected] => 
    [Header:protected] => 
    [Keywords:protected] => Array
        (
            [0] => Episurf Medical
            [1] => EpiSurf
            [2] => Pål Ryfors
        )
    [QuickFacts:protected] => Array
        (
        )
    [Categories:protected] => Array
        (
        )
    [Videos:protected] => Array
        (
        )
    [Files:protected] => Array
        (
            [0] => CisionBlockPro\Cision\File Object
                (
                    [IsMain:protected] => 1
                    [MediaType:protected] => File
                    [Url:protected] => https://mb.cision.com/Main/14691/3014446/1178024.pdf
                    [FileName:protected] => wkr0006.pdf
                    [Title:protected] => Episealer® to be presented at sports medicine meeting in Germany
                    [Description:protected] => Episealer® to be presented at sports medicine meeting in Germany
                    [CreateDate:protected] => 2020-01-22T08:15:13.577Z
                    [Keywords:protected] => Array
                        (
                        )
                    [Extension:protected] => pdf
                )
        )
    [Quotes:protected] => Array
        (
        )
    [ExternalLinks:protected] => Array
        (
        )
    [EmbeddedItems:protected] => Array
        (
        )
    [Id:protected] => 3545260
    [EncryptedId:protected] => E762E1942FF8791A
    [IsRegulatory:protected] => 
    [PublishDate:protected] => 2020-01-22T08:15:00Z
    [LastChangeDate:protected] => 2020-01-22T08:15:13.437Z
    [Title:protected] => Episealer® to be presented at sports medicine meeting in Germany
    [Intro:protected] => 
    [IptcCode:protected] => 04016003
    [InformationType:protected] => PRM
    [LanguageCode:protected] => en
    [CountryCode:protected] => se
    [CanonicalUrl:protected] => 
    [CisionWireUrl:protected] => https://news.cision.com/episurf/r/episealer--to-be-presented-at-sports-medicine-meeting-in-germany,c3014446
    [LanguageVersions:protected] => Array
        (
        )
    [Images:protected] => Array
        (
        )
    [Tickers:protected] => Array
        (
            [0] => stdClass Object
                (
                    [Symbol] => EPIS B
                    [ISIN] => SE0003491562
                    [PrimaryListing] => 1
                    [IsShare] => 1
                    [MarketPlaceSymbol] => STO
                    [MarketPlaceName] => Stockholmsbörsen
                    [MarketPlaceBloombergCode] => SS
                    [MarketPlaceMarketWireCode] => OMX
                    [MarketPlaceIsRegulated] => 1
                    [MarketPlaceCountryCode] => SE
                )
        )
)